Global Health Solutions, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Director Martin William Dewhurst was granted 71,666 stock options in Turn Therapeutics Inc. as part of the company's 2025 Omnibus Incentive Plan.
NASDAQ
Turn Therapeutics Inc. director Andrew Gengos was granted 95,000 stock options with an exercise price of $5.75.
NASDAQ
Director Arthur F. Golden was granted 89,584 stock options in Turn Therapeutics Inc. as part of the company's incentive plan.
NASDAQ
Director Kent Edward Kester was granted 83,334 stock options in Turn Therapeutics Inc. as part of the company's 2025 Omnibus Incentive Plan.
NASDAQ
Turn Therapeutics CEO Bradley Burnam transferred 600,000 shares of common stock to family trusts via gift transactions.
NASDAQ
Bradley Evan Burnam, CEO of Turn Therapeutics Inc., has acquired 300,000 shares of common stock, increasing his beneficial ownership.
NASDAQ
Director Arthur Golden reported the acquisition of 300,000 shares of common stock in Turn Therapeutics Inc. on April 2, 2026.
NASDAQ
Bradley Evan Burnam, CEO and Director of Turn Therapeutics Inc., reported the acquisition of stock options.
NASDAQ
Zuraiz Chaudhary, Interim CFO of Turn Therapeutics, acquired 80,000 employee stock options with an exercise price of $3.12.
NASDAQ
Turn Therapeutics director Martin William Dewhurst was granted 21,882 restricted stock units, vesting in full on January 7, 2027.
NASDAQ
Turn Therapeutics' Interim CFO, Zuraiz Chaudhary, purchased 2,500 shares of common stock at $3.50 per share, increasing direct beneficial ownership to 12,500 shares.
NASDAQ
Turn Therapeutics Director Arthur Golden increased his stake in the company by purchasing 9,868 shares of common stock at a weighted average price of $3.44.
NASDAQ
Arthur F. Golden, a Director at Turn Therapeutics Inc., purchased 20,532 shares of common stock at a weighted average price of $2.87 per share.
NASDAQ
Turn Therapeutics' Interim CFO, Zuraiz Chaudhary, increased his direct ownership in the company's common stock through two separate open market purchases.
NASDAQ
Turn Therapeutics' Interim CFO, Zuraiz Chaudhary, purchased 2,500 shares of common stock at a weighted average price of $3.62.
NASDAQ
Abraham Chesed, a Board Observer for Turn Therapeutics Inc., acquired 14,286 shares of common stock at $4.60 per share.
NASDAQ
Turn Therapeutics Inc. Interim CFO Zuraiz Chaudhary purchased 5,050 shares of common stock at $4.95 per share, effective October 23, 2025.
NASDAQ
Turn Therapeutics Director Arthur F. Golden purchased 20,202 shares of common stock for approximately $100,000, increasing his direct beneficial ownership to 30,202 shares.
NASDAQ
Turn Therapeutics Inc. Chief Medical Officer Neilesh Shailesh Ghodadra was granted 10,000 restricted stock units under the company's 2025 Omnibus Incentive Plan.
NASDAQ
Turn Therapeutics Inc. Director Kent Edward Kester was granted 10,000 restricted stock units under the company's 2025 Omnibus Incentive Plan.
NASDAQ
Turn Therapeutics' Interim CFO, Zuraiz Chaudhary, was granted 240,000 employee stock options under the company's 2025 Omnibus Incentive Plan.
NASDAQ
Turn Therapeutics Director Arthur F. Golden was awarded 10,000 Restricted Stock Units under the company's 2025 Omnibus Incentive Plan, vesting based on service or change in control.
NASDAQ
Turn Therapeutics Director Andrew Gengos received an award of 10,000 restricted stock units, vesting over one year or upon a change in control.